FACULTY
Craig Hofmeister, MD, MPH
Professor, Department of Hematology and Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia
Noopur S. Raje, MD
Director, Center for Multiple Myeloma
Rita Kelley Chair in Oncology
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
PROGRAM OVERVIEW
This enduring program is from the Multiple Myeloma Symposia held during the ASCO 2025 conference. It will focus on describing the mechanisms of action, efficacy and safety profiles of current and emerging therapies in multiple myeloma across different treatment settings. It integrates patient-specific factors, prognostic indicators, and current evidence to develop and implement personalized treatment plans across multiple lines of therapy. Additionally, the program addresses comprehensive management strategies for patients receiving immunotherapies, including referrals to specialized treatment centers, patient and caregiver education, expected outcomes, potential complications, and proactive monitoring protocols.
TARGET AUDIENCE
This activity is designed to meet the educational needs of academic and community hematologists/oncologists, oncology nurses, oncology NP/PAs, and oncology pharmacists to ensure the appropriate use of current and emerging therapies in relapsed/refractory multiple myeloma.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the mechanisms of action of current and emerging therapies in multiple myeloma, critically assessing their efficacy and safety profiles across different treatment settings
- Integrate patient-specific factors, prognostic indicators, and current evidence to design and implement personalized treatment plans for patients with multiple myeloma, integrating innovative antibody and immunotherapy platforms across all lines of therapy
- Develop comprehensive management strategies for patients with multiple myeloma receiving immunotherapies, addressing criteria and timing for referral to specialized treatment centers, patient and caregiver education on expected outcomes and potential complications, and proactive monitoring and management of unique toxicities related to treatment
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Speaker | Relationships | Manufacturer |
| Craig Hofmeister, MD | Consultant | Karyopharm Therapeutics |
| Contracted research | AbbVie and Sanofi | |
| Noopur S. Raje, MD | Consultant | Bristol Myers Squibb, Johnson & Johnson, Pfizer, Sanofi, GlaxoSmithKline, AstraZeneca, AbbVie, Regeneron, Immuneel Therapuetics, and Caribou Biosciences |
| Contracted research | Pfizer |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Deborah Anderson, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- M. Susan Burke, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: July 30, 2025
EXPIRATION DATE: July 30, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
